Sign in

Matthew L. Trerotola

CEO and Chair of the Board at Enovis
Board
Since July 2015
Age
57 years
Education
Holds a Master of Business Administration from Harvard Business School and a Bachelor of Science in Chemical Engineering from the University of Virginia.
Tenure
Joined as Chief Executive Officer in July 2015 and currently serves as Chair of the Board, after holding key leadership roles at DuPont and Danaher Corporation.

Also at Enovis

BRS
Brady R. Shirley
Executive Advisor
DAP
Daniel A. Pryor
Executive Vice President, Strategy and Business Development
LV
Louis Vogt
Group President, Reconstructive

About

Matthew L. Trerotola has been at the helm of Enovis Corporation since July 2015, where he serves as both Chief Executive Officer and Chair of the Board. His leadership at ENOV marks a significant phase in the company’s development, with his appointment driving strategic changes and growth initiatives.

Before joining ENOV, he built a robust career through senior roles at several prestigious companies. At DuPont, he served as an Executive Vice President responsible for the Electronics & Communications and Safety & Protection segments, along with oversight of the Asia-Pacific business. Earlier roles at Danaher Corporation, including Vice President and Group Executive for Life Sciences, as well as positions leading product identification and business operations, further showcase his extensive experience in the industry.

In addition to his executive roles, he is an active board member of AptarGroup, Inc., highlighting his broader influence in the corporate world. With a strong educational foundation from Harvard Business School and the University of Virginia, his career reflects a blend of advanced business acumen and technical expertise, positioning him as a seasoned leader in both operational and strategic capacities.

$ENOV Performance Under Matthew L. Trerotola

Past Roles

OrganizationRoleDate RangeDetails
DuPont Executive Vice President and Member of the Office of the Chief Executive 2013 – 2015 Oversaw the Electronics & Communications and Safety & Protection segments and managed the Asia-Pacific business
Danaher Corporation Vice President and Group Executive for Life Sciences 2012 – 2013 Held a leadership role focusing on strategic development in life sciences
Danaher Corporation Group Executive, Product Identification 2009 – 2012 Focused on product identification and strategic guidance
Danaher Corporation President of the Videojet Business 2007 – 2009 Led the Videojet business with emphasis on innovation and market growth
McKinsey & Company Consultant 1995 – 1999 Advised industrial companies to accelerate growth

External Roles

OrganizationRoleDate RangeDetails
AptarGroup, Inc. Director 2022 – Present Active role outside of ENOV

Fixed Compensation

Data from  FY 2023
Component NameAmountPayment ScheduleAdditional Details
Base Salary $1,077,000AnnualFixed annual base salary
Company 401(k)/Deferred Compensation Plan Match and Contribution $129,442AnnualIncludes both match and contribution components
Auto Allowance $20,000AnnualAnnual cash allowance for car-related expenses pursuant to his employment contract
Financial Services $15,250AnnualReimbursement for financial planning services
Aircraft Usage $282,344AnnualCompany expenses incurred for private plane usage for personal travel; billed directly
Supplemental Long-Term Disability Premiums $6,472AnnualPremium payments for supplemental long-term disability insurance
Group Term Life Insurance $8,748AnnualPremiums for a life insurance benefit equal to 1.5 times salary, capped at $1,125,000

Performance Compensation

Data from  FY 2023

Performance-Based Restricted Stock Units (PRSUs)

ParameterValueDetails
MetricRelative Total Shareholder Return (TSR) vs. S&P 500 Health Care Equipment & Supplies Industry Index Determines the payout scale based on percentile performance
Payout ScaleBelow Threshold: 0%; Threshold (30th percentile): 50%; Target (55th percentile): 100%; Maximum (>80th percentile): 200% (capped at 100% if absolute TSR is negative) Detailed performance brackets
Grant DateFebruary 28, 2023 The date the award was granted
Grant Date Fair Value$4,052,607 The fair value assigned on the grant date
Grant Date Stock Price$57.62 per share Reflects the exercise price for related stock options
Number of PRSUsThreshold: 28,222; Target: 56,443; Maximum: 112,886 Varies by performance outcome
VestingCliff vest at end of a three-year performance period Contingent upon certification by the CHCM Committee

Annual Incentive Plan (AIP)

ParameterValueDetails
Performance Metric 1Net Sales (as adjusted) Weight: 40%; Threshold: $1.588 billion; Target: $1.654 billion; Maximum: $1.786 billion; Achieved: $1.693 billion; CPF: 123%
Performance Metric 2Adjusted EBITDA Weight: 60%; Threshold: $228 million; Target: $260 million; Maximum: $325 million; Achieved: $269 million; CPF: 121%
Weighted Aggregate CPF122% Combined corporate performance factor
Bonus CalculationBase Salary: $1,077,000; Target Bonus Percentage: 125%; Target Bonus: $1,346,250; Bonus Before IPF: $1,642,425; Individual Performance Factor: 110%; Executive Bonus Payment: $1,806,668 Bonus metrics derived from performance results
Equity Grant DetailsPRSUs: $4,052,607; RSUs: $1,626,094; Stock Options: $1,750,010 Grant Date: February 28, 2023; Stock Options vest ratably over three years starting on February 28, 2024

*Note: All performance compensation metrics reflect the 2023 awards with performance evaluations based on both operational and financial targets, and vest over varying periods as noted above. *